SKIN PROTECTION
n Active (2260115.A/IBRN2981-1) n Placebo (2260115.B/IBRN2981-2)
0.0 –3.0 –6.0 –9.0 –12.0 –15.0 –18.0
–1.4 –6.7 –9.7 NS
–16.5 *
Day 14 Figure 7: Roughness variation.
Study design This study was conducted double blind, comparing an active with 1% Asteriscus graveolens extract vs. placebo (cream-gel chassis). The 25 subjects were all female (aged 46-60) with ‘heavy smoking habits’ (>10 cigarettes/day), and ‘with ageing signs’ in the periocular (eye) area and the corner of the mouth. Split-face (left/right) application twice
daily was carried out for 4 weeks, with measures taken on D0, D14, and D28. Measurements were taken using:
l Visia CA: standardised imaging with normal, cross-polarised, and UV illumination.
l Wrinkles and roughness evaluation by Primos 3D.
Day 28
l Skin hydration by Corneometer. l Skin elasticity by Cutometer. l Skin colour (as L,a,b) by colorimeter (Minolta).
l Clinical assessment by a trained clinician, under standardised ‘daylight’ illumination – wrinkles (picture-based scale), roughness, suppleness, evenness of complexion, texture.
l Subjective self-assessment by questionnaire.
The study was carried out at PhD laboratories (Portugal) - PhD labs study number 2260115.
Results Twice-daily use of a cream with 1% Asteriscus graveolens extract, compared to placebo, for 28 days, results in good anti- ageing (anti-wrinkle) efficacy, with the Primos analysis showing a strong decrease in wrinkle count and improvement in skin texture. The clinical evaluation revealed strong improvement in wrinkle grades, skin roughness, and texture. There was a small but significant skin , b*
lightening effect (L* , ITA˚) as well as Asteriscus graveolens.
a steady improvement in skin hydration (corneometer). Improvements in skin firmness were confirmed by Cutometer and the Visia analysis showed small
n Active (2260115.A/IBRN2981-1) n Placebo (2260115.B/IBRN2981-2)
3.0 NS 0.0 0.5 –0.2 0.7 * 2.5 –3.0 Day 14 Figure 9: L* variation. 58 PERSONAL CARE September 2015 Day 28
18.0 15.0 12.0 9.0 6.0 3.0 0.0
0.0 –3.0 –6.0 –9.0 –12.0 –15.0 –18.0 –21.0
n Active (2260115.A/IBRN2981-1) n Placebo (2260115.B/IBRN2981-2)
–6.3 –9.4 NS
–18.3 *
Day 14 Figure 8: Texture variation.
improvements in wrinkles, spots (brown, UV, visible). Subjective evaluation confirmed significant improvements in skin tone, radiance, spots, sensitivity, wrinkles, visible health, and visible youthfulness.
Primos The active product exhibits good anti- ageing efficacy, expressed as: a strong and significant reduction in wrinkle count, and a significant reduction in wrinkles volume (data shown was taken in the periorbital region).
Clinical evaluation of wrinkles Confirming the instrumental measurements above, clinical evaluation reveals a significant anti-ageing effect, expressed as a significant reduction in wrinkle score vs. baseline and placebo (placebo shows no effect).
Clinical evaluation and other parameters Use of the active product resulted in: l A moderate but significant improvement in skin roughness grades (vs. baseline and placebo).
l A moderate but significant improvement in skin texture grades (vs. baseline and placebo).
n Active (2260115.A/IBRN2981-1) n Placebo (2260115.B/IBRN2981-2)
* 14.6 Day 28 –10.4
NS 4.3 0.6 Day 14 Figure 10: ITA˚ variation. Day 28 4.4
Change (%)
Change (%)
Change (%)
Change (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
